Global Ulcerative Colitis Market Report 2024

Ulcerative Colitis Global Market Report 2024 – By Drug Type (Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types), By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis), By Molecule Type (Biologics, Small Molecules), By Route of Administration (Oral, Injectables), By End-User (Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User) – Market Size, Trends, And Global Forecast 2024-2033

Ulcerative Colitis Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Ulcerative Colitis Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Ulcerative Colitis Market Definition And Segments

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) and is categorized as an autoimmune disorder in which the immune system attacks healthy tissue of the large intestine and causes inflammation on the superficial layer of the large intestine. It includes symptoms of diarrhea, weight loss, abdominal cramping, anemia, blood or pus in bowel movements, and others.

The main types of drugs for ulcerative colitis are anti-inflammatory drugs, anti-TNF biologics, immunosuppressants, calcineurin inhibitors, and others. Anti-inflammatory drugs refer to a drug or substance that reduces inflammation (redness, swelling, and pain) in the body. These are prescribed for various diseases such as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis, with molecule types including biologics and small molecules, which can be administered orally or injectable. It is used by various end-users, including hospital pharmacies, retail pharmacies, drug stores, and others.

The ulcerative colitis market covered in this report is segmented –

1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types

2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis

3) By Molecule Type: Biologics, Small Molecules

4) By Route of Administration: Oral, Injectables

5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User

The ulcerative colitis market size has grown strongly in recent years. It will grow from $6.84 billion in 2023 to $7.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to prevalence of ulcerative colitis, innovations in drug development, biologics and targeted therapies, improved treatment guidelines, patient advocacy and support groups.

The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in telemedicine, focus on early intervention, biosimilars market growth, research in gut microbiome, emergence of novel therapies. Major trends in the forecast period include patient-centric approaches, global collaborations in research, integration of digital health solutions, innovations in drug delivery, topical and localized therapies.

Fueling Growth Ulcerative Colitis Market Expands With The Surge In Healthcare Expenditure

The increasing healthcare expenditure is expected to propel the growth of the ulcerative colitis market going forward. Health expenditure refers to all spending for health-related services, family planning activities, nutrition activities, and emergency help, but excludes expenses for drinking water and sanitation. Increased healthcare spending can benefit ulcerative colitis sufferers by improving access to medical care and therapies. Hospitalization for ulcerative colitis can be significant, and hospital readmissions for flares can result in higher mortality and healthcare costs. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021–2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, increasing healthcare expenditures are driving the growth of the ulcerative colitis market.

Navigating Growth Rising Prevalence And Incidence Fuel Expansion Of Ulcerative Colitis Market

The increasing prevalence and incidence of ulcerative colitis are expected to propel the growth of the ulcerative colitis market in the coming future. Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that primarily impacts the colon and rectum, marked by ulcers and inflammation in the lining of the large intestine (colon) and rectum, resulting in a variety of symptoms and problems. The growing incidence and prevalence of ulcerative colitis serve as stimulants, encouraging innovation, expansion, and an emphasis on bettering patient outcomes. For instance, in January 2022, according to Crohn’s & Colitis Australia, an Australia-based non-profit organization that provides people with inflammatory bowel disease support, guidance, and encouragement, Australia is projected to have between 100,000 and 160,000 patients with Crohn's disease and ulcerative colitis by 2022. Therefore, the increasing prevalence and incidence of ulcerative colitis are driving the ulcerative colitis market.

Major companies operating in the ulcerative colitis market report are Abbott Laboratories, AbbVie Inc., Ajinomoto Co. Inc., AstraZeneca PLC, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, Index Pharmaceuticals Holdings AB, GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan PLC, Bayer AG, BioLineRx Ltd., Celgene Corporation, Bristol Myers Squib Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Protagonist Therapeutics, Shire PLC, Warner Chilcott, Prometheus Laboratories Inc., Cosmo Pharmaceuticals, Dr. Falk Pharma GmbH, Tillotts Pharma AG, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc.

Revolutionizing IBD Diagnosis Clario Ert Inc., Gi Reviewers LLC, And Rsip Vision Unveil AI Technology For Enhanced Ulcerative Colitis Scoring

Technological advancements are a key trend gaining popularity in the ulcerative colitis market. Companies operating in the ulcerative colitis market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Clario ERT Inc., a US-based healthcare research and technology firm, and GI Reviewers LLC, a US-based pharmaceutical reviews and assessment organization, along with RSIP Vision, an ISRAEL-based software company, released their innovative and human-level AI technology-based rating system to improve efficiency and consistency of inflammatory bowel disease (IBD) scoring, such as ulcerative colitis (UC) and Crohn’s disease scoring. The method is projected to enhance the repeatability of colonoscopy video scoring, streamline workflow by reducing the time necessary for a human expert reader to score, and, eventually, boost recruitment and lower clinical trial expenses. The performance of algorithms, as measured by the Kappa metric technology, was shown to be equivalent to that of human reviewers. The algorithm was trained on hundreds of films from various sites and devices, comprising over 100,000 photos, all of which were assessed by an expert gastroenterologist.

Sanofi S.A. And Teva Pharmaceuticals Forge Strategic Partnership To Advance Tev'574 In The Treatment Of Crohn's Disease And Ulcerative Colitis

Major companies operating in the ulcerative colitis market are adopting a strategic partnership approach aiming to jointly develop and market pharmaceuticals that are presently being developed. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in October 2023, Sanofi S.A., a France-based healthcare and pharmaceutical company, announced a partnership with Teva Pharmaceuticals to jointly develop and market the asset TEV'574, which is presently undergoing Phase 2b clinical studies to treat Crohn's disease and ulcerative colitis, two forms of inflammatory bowel illness. Teva will be paid an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in milestones related to development and commercialization under the provisions of the new collaboration agreement. Sanofi will spearhead the development of the Phase 3 program, and all companies will equally split the development costs worldwide as well as net earnings and losses in important markets. Sanofi will manage North American, Japanese, other Asian, and worldwide product commercialization; Teva will lead the charge in Europe, Israel, and a few other nations. Teva Pharmaceuticals is a US-based subsidiary company of Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical company.

Pfizer Inc. Expands Inflammation And Immunology Portfolio With Acquisition Of Arena Pharmaceuticals Inc.

In March 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired Arena Pharmaceuticals Inc. for approximately $6.7 billion. This acquisition aims to expand Pfizer's existing inflammation and immunology pipeline portfolio of drugs into its inflammation and immunology therapeutic area, which will aid in the goal of generating breakthroughs to improve the lives of people suffering from immuno-inflammatory disorders. Arena Pharmaceuticals Inc. is a US-based biopharmaceutical company and developer of Etrasimod, a highly selective, once-daily oral sphingosine 1-phosphate (S1P) receptor modulator that is used for the treatment of ulcerative colitis, Crohn’s disease, and others.

North America was the largest region in the ulcerative colitis market in 2023. The regions covered in the ulcerative colitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ulcerative colitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ulcerative colitis market consists of sales of aminosalicylates and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The ulcerative colitis market research report is one of a series of new reports from The Business Research Company that provides ulcerative colitis market statistics, including ulcerative colitis industry global market size, regional shares, competitors with an ulcerative colitis market share, detailed ulcerative colitis market segments, market trends and opportunities, and any further data you may need to thrive in the ulcerative colitis industry. This ulcerative colitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Ulcerative Colitis Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $7.35 billion
Revenue Forecast In 2033 $9.48 billion
Growth Rate CAGR of 6.6% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types
2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis
3) By Molecule Type: Biologics, Small Molecules
4) By Route of Administration: Oral, Injectables
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Abbott Laboratories; AbbVie Inc.; Ajinomoto Co. Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Eli Lilly and Co.; Johnson & Johnson; Index Pharmaceuticals Holdings AB; GlaxoSmithKline plc; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Sanofi S.A.; Allergan plc; Bayer AG; BioLineRx Ltd.; Celgene Corporation; Bristol Myers Squib Company; Takeda Pharmaceutical Company Limited; Genentech Inc.; UCB S.A.; Protagonist Therapeutics; Shire plc; Warner Chilcott; Prometheus Laboratories Inc.; Cosmo Pharmaceuticals; Dr. Falk Pharma GmbH; Tillotts Pharma AG; Ferring Pharmaceuticals Inc.; Salix Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Ulcerative Colitis Market Characteristics

    3. Ulcerative Colitis Market Trends And Strategies

    4. Ulcerative Colitis Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Ulcerative Colitis Market Size and Growth

    5.1. Global Ulcerative Colitis Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Ulcerative Colitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Ulcerative Colitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Ulcerative Colitis Market Segmentation

    6.1. Global Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Anti-Inflammatory Drugs

    Anti-TNF Biologics

    Immunosuppressant

    Calcineurin Inhibitors

    Other Drug Types

    6.2. Global Ulcerative Colitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Ulcerative Proctitis

    Proctosigmoiditis

    Left-sided Colitis

    Pancolitis or Universal Colitis

    Fulminant Colitis

    6.3. Global Ulcerative Colitis Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Biologics

    Small Molecules

    6.4. Global Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Injectables

    6.5. Global Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Drug Store

    Other End-User

    7. Ulcerative Colitis Market Regional And Country Analysis

    7.1. Global Ulcerative Colitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Ulcerative Colitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Ulcerative Colitis Market

    8.1. Asia-Pacific Ulcerative Colitis Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Ulcerative Colitis Market

    9.1. China Ulcerative Colitis Market Overview

    9.2. China Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Ulcerative Colitis Market

    10.1. India Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Ulcerative Colitis Market

    11.1. Japan Ulcerative Colitis Market Overview

    11.2. Japan Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Ulcerative Colitis Market

    12.1. Australia Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Ulcerative Colitis Market

    13.1. Indonesia Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Ulcerative Colitis Market

    14.1. South Korea Ulcerative Colitis Market Overview

    14.2. South Korea Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Ulcerative Colitis Market

    15.1. Western Europe Ulcerative Colitis Market Overview

    15.2. Western Europe Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Ulcerative Colitis Market

    16.1. UK Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Ulcerative Colitis Market

    17.1. Germany Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Ulcerative Colitis Market

    18.5. France Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Ulcerative Colitis Market

    19.9. Italy Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Ulcerative Colitis Market

    20.13. Spain Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Ulcerative Colitis Market

    21.1. Eastern Europe Ulcerative Colitis Market Overview

    21.2. Eastern Europe Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Ulcerative Colitis Market

    22.1. Russia Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Ulcerative Colitis Market

    23.1. North America Ulcerative Colitis Market Overview

    23.2. North America Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Ulcerative Colitis Market

    24.1. USA Ulcerative Colitis Market Overview

    24.2. USA Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Ulcerative Colitis Market

    25.1. Canada Ulcerative Colitis Market Overview

    25.2. Canada Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Ulcerative Colitis Market

    26.1. South America Ulcerative Colitis Market Overview

    26.2. South America Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Ulcerative Colitis Market

    27.1. Brazil Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Ulcerative Colitis Market

    28.1. Middle East Ulcerative Colitis Market Overview

    28.2. Middle East Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Ulcerative Colitis Market

    29.1. Africa Ulcerative Colitis Market Overview

    29.2. Africa Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Ulcerative Colitis Market Competitive Landscape And Company Profiles

    30.1. Ulcerative Colitis Market Competitive Landscape

    30.2. Ulcerative Colitis Market Company Profiles

    30.2.1. Abbott Laboratories

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. AbbVie Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Ajinomoto Co. Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AstraZeneca plc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Bausch Health Companies Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Ulcerative Colitis Market Competitive Benchmarking

    32. Global Ulcerative Colitis Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Ulcerative Colitis Market

    34. Ulcerative Colitis Market Future Outlook and Potential Analysis

    34.1 Ulcerative Colitis Market In 2028 - Countries Offering Most New Opportunities

    34.2 Ulcerative Colitis Market In 2028 - Segments Offering Most New Opportunities

    34.3 Ulcerative Colitis Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Ulcerative Colitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Ulcerative Colitis Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Ulcerative Colitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Ulcerative Colitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Abbott Laboratories Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Ajinomoto Co. Inc. Financial Performance
  • Table 79: AstraZeneca plc Financial Performance
  • Table 80: Bausch Health Companies Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Ulcerative Colitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Ulcerative Colitis Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Ulcerative Colitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Ulcerative Colitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Ulcerative Colitis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Ulcerative Colitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Ulcerative Colitis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Abbott Laboratories Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Ajinomoto Co. Inc. Financial Performance
  • Figure 79: AstraZeneca plc Financial Performance
  • Figure 80: Bausch Health Companies Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the ulcerative colitis market?

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) and is categorized as an autoimmune disorder in which the immune system attacks healthy tissue of the large intestine and causes inflammation on the superficial layer of the large intestine. It includes symptoms of diarrhea, weight loss, abdominal cramping, anemia, blood or pus in bowel movements, and others. For further insights on the ulcerative colitis market, request a sample here

How will the ulcerative colitis market drivers and restraints affect the ulcerative colitis market dynamics? What forces will shape the ulcerative colitis industry going forward?

The ulcerative colitis market major growth driver - fueling growth ulcerative colitis market expands with the surge in healthcare expenditure. For further insights on the ulcerative colitis market, request a sample here

What is the forecast market size or the forecast market value of the ulcerative colitis market ?

The ulcerative colitis market size has grown strongly in recent years. It will grow from $6.84 billion in 2023 to $7.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to prevalence of ulcerative colitis, innovations in drug development, biologics and targeted therapies, improved treatment guidelines, patient advocacy and support groups. The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in telemedicine, focus on early intervention, biosimilars market growth, research in gut microbiome, emergence of novel therapies. Major trends in the forecast period include patient-centric approaches, global collaborations in research, integration of digital health solutions, innovations in drug delivery, topical and localized therapies. For further insights on the ulcerative colitis market, request a sample here

How is the ulcerative colitis market segmented?

The ulcerative colitis market is segmented
1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types
2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis
3) By Molecule Type: Biologics, Small Molecules
4) By Route of Administration: Oral, Injectables
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-UserFor further insights on the ulcerative colitis market,
request a sample here

Which region has the largest share of the ulcerative colitis market? What are the other regions covered in the report?

North America was the largest region in the ulcerative colitis market in 2023. The regions covered in the ulcerative colitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the ulcerative colitis market, request a sample here.

Who are the major players in the ulcerative colitis market?

Major companies operating in the ulcerative colitis market report are Abbott Laboratories, AbbVie Inc., Ajinomoto Co. Inc., AstraZeneca plc, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, Index Pharmaceuticals Holdings AB, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Bayer AG, BioLineRx Ltd., Celgene Corporation, Bristol Myers Squib Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Protagonist Therapeutics, Shire plc, Warner Chilcott, Prometheus Laboratories Inc., Cosmo Pharmaceuticals, Dr. Falk Pharma GmbH, Tillotts Pharma AG, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc. For further insights on the ulcerative colitis market, request a sample here.

What are the key trends in the ulcerative colitis market?

Major trend in the ulcerative colitis market - revolutionizing ibd diagnosis clario ert inc., gi reviewers llc, and rsip vision unveil ai technology for enhanced ulcerative colitis scoring. For further insights on the ulcerative colitis market, request a sample here.

What are the major opportunities in the ulcerative colitis market? What are the strategies for the ulcerative colitis market?

For detailed insights on the major opportunities and strategies in the ulcerative colitis market, request a sample here.

How does the ulcerative colitis market relate to the overall economy and other similar markets?

For detailed insights on ulcerative colitis market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the ulcerative colitis industry?

For detailed insights on the mergers and acquisitions in the ulcerative colitis industry, request a sample here.

What are the key dynamics influencing the ulcerative colitis market growth? SWOT analysis of the ulcerative colitis market.

For detailed insights on the key dynamics influencing the ulcerative colitis market growth and SWOT analysis of the ulcerative colitis industry, request a sample here.